Metabolic diseases affecting bone are generally diagnosed late when patients present clinically with end stage skeletal debilitation. This is the result of their subclinical progression and the lack of unequivocal biochemical-or radiological techniques to identify bone changes at an early stage. This manuscript presents histomorphometry as a quantifiable method for the accurate assessment of metabolic bone disease at cellular level.

This article was not submitted to an ethical committee for approval. The content of this article is the sole work of the author. No benefits of any form have been derived from any commercial party related directly or indirectly to the subject of this article.